MetaCap

Gilead Sciences (GILD) vs Revolution Medicines (RVMD)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.

Summary

Revolution Medicines (RVMD) has outperformed Gilead Sciences (GILD) over the past year, gaining 293.4% versus a gain of 24.4%. Over five years, RVMD leads with a +598.0% price change compared with +117.5% for GILD. Gilead Sciences is the larger company by market cap ($182.40 billion vs $40.32 billion), about 4.5 times the size.

Gilead Sciences pays a dividend yielding 2.19%, while Revolution Medicines does not currently pay one.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

GILD+24.40%RVMD+293.39%
+381%+181%-19%
Oct 8, 20251 yearOct 8, 2026
GILD+116.16%RVMD+577.18%
+691%+306%-79%
Oct 4, 20215 yearsOct 5, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

GILD versus RVMD key metrics
MetricGILDRVMD
Share price$147.10$188.12
Market cap$182.40B$40.32B
1-day change+0.17%-6.35%
YTD return+19.85%+136.18%
1-year return+24.40%+293.39%
5-year return+117.51%+598.03%
Forward P/E14.87—
EPS (TTM)$-2.65$-8.87
Dividend yield2.19%0.00%
Annual dividend$3.22$0.00
Revenue (latest FY)$29.44B$0
Revenue growth (YoY)+2.40%—
Net income (latest FY)$8.51B$-1.13B
Gross margin78.83%—
Operating margin34.04%—
Net margin28.90%—
52-week high$157.29$224.31
52-week low$114.02$47.28
Distance from 52-week high-6.48%-16.13%
Analyst consensusbuystrong_buy
Avg. price target upside+8.27%+37.59%
Average volume5.99M1.88M
Shares outstanding1.24B214.34M
Employees17,000883
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Gilead Sciences is about 4.5 times larger than Revolution Medicines by market value ($182.40B vs $40.32B).
  • RVMD has outperformed GILD by 269.0 percentage points over the past year.
  • Gilead Sciences offers a meaningfully higher dividend yield (2.19% vs 0.00%).

About Gilead Sciences

GILD stock →

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 17,000 employees

About Revolution Medicines

RVMD stock →

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 883 employees

GILD vs RVMD FAQ

Which is bigger, Gilead Sciences or Revolution Medicines?

Gilead Sciences (GILD) is larger, with a market capitalization of $182.40B compared with $40.32B for Revolution Medicines (RVMD).

Which stock has performed better over the past year, GILD or RVMD?

RVMD returned +293.39% over the past 12 months, compared with +24.40% for GILD (price return, excluding dividends). Past performance does not predict future results.

Which pays a higher dividend, Gilead Sciences or Revolution Medicines?

Gilead Sciences pays a dividend yielding 2.19%, while Revolution Medicines does not currently pay a regular dividend.

Are Gilead Sciences and Revolution Medicines in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons